Your browser doesn't support javascript.
loading
The Proportion of APOE4 Carriers Among Non-Demented Individuals: A Pooled Analysis of 389,000 Community-Dwellers.
Wang, Ya-Yu; Ge, Yi-Jun; Tan, Chen-Chen; Cao, Xi-Peng; Tan, Lan; Xu, Wei.
Afiliação
  • Wang YY; Department of Neurology, Qingdao Municipal Hospital, Dalian Medical University, Dalian, China.
  • Ge YJ; Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
  • Tan CC; Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
  • Cao XP; Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
  • Tan L; Department of Neurology, Qingdao Municipal Hospital, Dalian Medical University, Dalian, China.
  • Xu W; Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
J Alzheimers Dis ; 81(3): 1331-1339, 2021.
Article em En | MEDLINE | ID: mdl-33935087
ABSTRACT

BACKGROUND:

The apolipoprotein E epsilon 4 (APOE4) is the strongest genetic risk factor for sporadic Alzheimer's disease (AD). Its carriage percentage in non-demented population varies across geographic regions and ethnic groups.

OBJECTIVE:

To estimate the proportion of APOE4 (2/4, 3/4, or 4/4) carriers in non-demented community-dwellers.

METHODS:

PubMed, EMBASE, and China National Knowledge Infrastructure were searched from inception to April 20, 2020. Community-based studies that reported APOE polymorphisms with a sample of≥500 non-demented participants were included. Random-effects models were used to pool the results. Meta-regression and subgroup analyses were performed to test the source of heterogeneity and stratified effects. Age-standardized pooled proportion estimates (ASPPE) were calculated by direct standardization method.

RESULTS:

A total of 121 studies were included, with a pooled sample of  389,000 community-dwellers from 38 countries. The global average proportion of APOE4 carriers was 23.9% (age-standardized proportion 26.3%; 2.1% for APOE4/4, 20.6% for APOE3/4 and 2.3% for APOE2/4), and varied significantly with geographical regions (from 19.3% to 30.0%) and ethnic groups (from 19.1% to 37.5%). The proportion was highest in Africa, followed by Europe, North America, Oceania, and lowest in South America and Asia (p < 0.0001). With respect to ethnicity, it was highest in Africans, followed by Caucasians, and was lowest in Hispanics/Latinos and Chinese (p < 0.0001).

CONCLUSION:

APOE4 carriers are common in communities, especially in Africans and Caucasians. Developing precision medicine strategies in this specific high-risk population is highly warranted in the future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimorfismo de Nucleotídeo Único / Apolipoproteína E4 / Doença de Alzheimer / Heterozigoto Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: J Alzheimers Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimorfismo de Nucleotídeo Único / Apolipoproteína E4 / Doença de Alzheimer / Heterozigoto Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: J Alzheimers Dis Ano de publicação: 2021 Tipo de documento: Article